Market Cap

PolyPeptide Group AG Market Capitalization:

CHF692.9 Million

CHF as of July 1, 2025

US$876.3 Million

business PolyPeptide Group AG Company Profile

PolyPeptide Group AG Main Stock Listing

SIX: PPGN

Market Capitalization History of PolyPeptide Group AG

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic
Company Market Cap (USD)
MERCK Kommanditgesellschaft auf Aktien $62.01 B
Zoetis Inc. $55.81 B
Takeda Pharmaceutical Company Limited $45.42 B
Haleon plc $44.50 B
Teva Pharmaceutical Industries Limited $35.85 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $968.50 B
Johnson & Johnson $499.57 B
AbbVie $405.28 B
Roche $332.12 B
UnitedHealth Group $304.72 B

Yearly evolution of PolyPeptide Group AG market cap

Date Market Cap YoY Change
Jan. 1, 2025 CHF923.5 M 65.20%
Jan. 1, 2024 CHF559.1 M -38.50%
Jan. 1, 2023 CHF909.0 M -70.24%
Jan. 1, 2022 CHF3.05 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

PolyPeptide Group AG Categories

Switzerland languages Healthcare languages Drug Manufacturers—Specialty & Generic
Switzerland Healthcare Switzerland Drug Manufacturers—Specialty & Generic

Stocks & Indices

PolyPeptide Group AG has the following listings and related stock indices.


Stock: SIX: PPGN

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.